Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
Laura Riva
Ok-ryul Song
Jannick Prentoe
François Helle
Laurent L'homme
Charles-Henry Gattolliat
Alexandre Vandeputte
Lucie Fénéant
Sandrine Belouzard
Thomas F. Baumert
Tarik Asselah
Jens Bukh
Priscille Brodin
Laurence Cocquerel
Yves Rouillé
Jean Dubuisson
Michael S. Diamond
Journal of Virology, 2018
Laurence Cocquerel
Cocquerel Laurence
ORCID: 0000-0002-2136-5178
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus
10.1128/jvi.00404-16
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/jvi.00192-15
SRFBP1, an Additional Player in HCV Entry
10.1016/j.tim.2015.08.003
CD81 and Hepatitis C Virus (HCV) Infection
10.3390/v6020535
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
10.1371/journal.pone.0111333
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry
10.1111/cmi.12112
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Structural Basis of Ligand Interactions of the Large Extracellular Domain of Tetraspanin CD81
10.1128/jv1.00559-12
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection
10.1074/jbc.M111.220103
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
10.1186/1471-2180-9-111
The Ig Domain Protein CD9P-1 Down-regulates CD81 Ability to Support Plasmodium yoelii Infection
10.1074/jbc.M109.057927
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Entry of HCV into target cells
10.1684/vir.2008.0163
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
Hepatitis C virus entry: potential receptors and their biological functions
10.1099/vir.0.81646-0
Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop
10.1016/j.bbrc.2005.01.056
Characterization of functional hepatitis C virus envelope glycoproteins
10.1128/jvi.78.6.2994-3002.2004
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions
10.1074/jbc.M406315200
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
10.1128/jvi.77.19.10677-10683.2003
Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody
10.1128/jvi.77.2.1604-1609.2003
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line
10.1093/glycob/12.2.95
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
10.1128/jvi.76.8.3720-3730.2002
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins
10.1093/emboj/cdf295
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10.1128/jvi.74.8.3623-3633.2000
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein
10.1074/jbc.M004326200
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
10.1074/jbc.273.48.32088
[Occludin, an additional key for hepatitis C virus entry].
10.1051/medsci/2009256-7549
HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses.
10.1053/j.gastro.2009.11.018
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies.
10.1016/j.yexcr.2011.08.018
Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81.
10.1128/jvi.00559-12
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.
10.1136/gutjnl-2015-311109
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein.
10.1053/j.gastro.2017.09.020
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization.
10.1074/jbc.m003003200
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication.
10.1111/cmi.12804
The Role of CD81 in HCV and Plasmodium Infection
10.1007/978-94-007-6070-7_14
Biogenesis of hepatitis C virus envelope glycoproteins
10.1099/0022-1317-82-11-2589
Endoplasmic reticulum retention of hepatitis C virus glycoprotein complex E1E2: A role for the transmembrane domain of E2
10.1016/s0248-4900(98)80287-6
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2
10.1099/0022-1317-82-7-1629
SOLUTION STRUCTURE OF FRAGMENT (350-370) OF THE TRANSMEMBRANE DOMAIN OF HEPATITIS C ENVELOPE GLYCOPROTEIN E1
10.2210/pdb1emz/pdb
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1038/s41598-019-42737-2
Le virus de l’hépatite E, un virus méconnu qui se dévoile
10.1051/medsci/2018299
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis
10.1093/infdis/jiz171
The fate of Hepatitis E virus capsid protein is regulated by an Arginine-Rich Motif
10.1101/2021.05.26.445820
In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus.
10.1007/s40203-021-00093-y
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1101/435933
Yves Rouillé
Rouillé Yves
ORCID: 0000-0003-0788-9271
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon
10.1016/s0014-5793(97)00892-2
Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1
10.1074/jbc.272.52.32810
Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: A potential mechanism for its inactivation
10.1073/pnas.93.10.4919
DISTINCT HYDRO-OSMOTIC RECEPTORS FOR THE NEUROHYPOPHYSEAL PEPTIDES VASOTOCIN AND HYDRINS IN THE FROG RANA-ESCULENTA
10.1016/0143-4179(95)90039-x
HYPERPROINSULINAEMIA IN OBESE FAT/FAT MICE ASSOCIATED WITH A CARBOXYPEPTIDASE-E MUTATION WHICH REDUCES ENZYME-ACTIVITY
10.1038/ng0695-135
PROTEOLYTIC PROCESSING MECHANISMS IN THE BIOSYNTHESIS OF NEUROENDOCRINE PEPTIDES - THE SUBTILISIN-LIKE PROPROTEIN CONVERTASES
10.1006/frne.1995.1012
ACTION OF NEUROHYPOPHYSEAL GRANULE LYS-ARG ENDOPEPTIDASE ON SYNTHETIC POLYPEPTIDES COMPRISING THE PROCESSING SEQUENCE OF PROVASOPRESSIN-NEUROPHYSIN
10.1007/bf01200246
PROGLUCAGON IS PROCESSED TO GLUCAGON BY PROHORMONE CONVERTASE PC2 IN ALPHA-TC1-6 CELLS
10.1073/pnas.91.8.3242
SPECIAL EVOLUTION OF NEUROHYPOPHYSEAL HORMONES IN CARTILAGINOUS FISHES - ASVATOCIN AND PHASVATOCIN, 2 OXYTOCIN-LIKE PEPTIDES ISOLATED FROM THE SPOTTED DOGFISH (SCYLIORHINUS-CANICULUS)
10.1073/pnas.91.23.11266
A NEUROSECRETORY GRANULE LYS-ARG CA2+-DEPENDENT ENDOPEPTIDASE PUTATIVELY INVOLVED IN PROOXYTOCIN AND PROVASOPRESSIN PROCESSING
10.1016/0143-4179(92)90050-7
EVIDENCE FOR DISTINCT DIBASIC PROCESSING ENDOPEPTIDASES WITH LYS-ARG AND ARG-ARG SPECIFICITIES IN NEUROHYPOPHYSEAL SECRETORY GRANULES
10.1016/0006-291x(92)91618-z
PROCESSING ENDOPEPTIDASE DEFICIENCY IN NEUROHYPOPHYSEAL SECRETORY GRANULES OF THE DIABETES-INSIPIDUS (BRATTLEBORO) RAT
10.1007/bf01122032
HETEROLOGUE CONVERSION OF AMPHIBIAN HYDRIN-2 INTO VASOTOCIN THROUGH BOVINE GRANULE ALPHA-AMIDATING ENZYME
10.1111/j.1365-2826.1991.tb00233.x
NEUROHYPOPHYSEAL HORMONES AS MOLECULAR EVOLUTIONARY TRACERS - INVESTIGATIONS ON THE STURGEONS ACIPENSER-STELLATUS AND ACIPENSER-GULDENSTADTI
10.1016/0305-0491(91)90280-q
EVOLUTIONARY SPECIFICITY OF HYDRINS, NEW HYDROOSMOTIC NEUROPEPTIDES - OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY) IN THE TOAD BUFO-MARINUS BUT NOT IN THE VIPER VIPERA-ASPIS
10.1016/0014-5793(90)80783-f
IDENTIFICATION OF 2 TYPES OF NEUROPHYSINS IN XENOPUS-LAEVIS NEUROINTERMEDIATE PITUITARY HOMOLOGOUS TO MAMMALIAN MSEL-NEUROPHYSIN AND VLDV-NEUROPHYSIN
10.1016/0143-4179(90)90142-l
OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY), A NEW HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDE, IN SECRETORY GRANULES ISOLATED FROM THE FROG (RANA-ESCULENTA) NEUROINTERMEDIATE PITUITARY
10.1159/000125343
HYDRINS, HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDES - OSMOREGULATORY ADAPTATION IN AMPHIBIANS THROUGH VASOTOCIN PRECURSOR PROCESSING
10.1073/pnas.86.14.5272
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOTOCIN, MESOTOCIN, MSEL-NEUROPHYSINS AND VLDV-NEUROPHYSINS FROM GOOSE NEUROHYPOPHYSIS
10.1016/0143-4179(89)90090-5
PARTICULAR PROCESSING OF PRO-OPIOMELANOCORTIN IN XENOPUS-LAEVIS INTERMEDIATE PITUITARY - SEQUENCING OF ALPHA-MELANOCYTE-STIMULATING, AND BETA-MELANOCYTE-STIMULATING HORMONES
10.1016/0014-5793(89)80224-8
DUAL DUPLICATION OF NEUROHYPOPHYSEAL HORMONES IN AN AUSTRALIAN MARSUPIAL - MESOTOCIN, OXYTOCIN, LYSINE VASOPRESSIN AND ARGININE VASOPRESSIN IN A SINGLE GLAND OF THE NORTHERN BANDICOOT (ISOODON-MACROURUS)
10.1016/0006-291x(88)90691-2
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOPRESSIN AND MSEL-NEUROPHYSIN FROM GUINEA-PIG NEUROINTERMEDIATE PITUITARY
10.1016/0143-4179(88)90025-x
NEUROHYPOPHYSEAL HORMONES OF THE 1-MONTH-OLD BOVINE FETUS - ABSENCE OF VASOTOCIN DURING MAMMAL DEVELOPMENT
10.1016/0014-5793(88)80113-3
THE DISTRIBUTION OF LYSINE VASOPRESSIN (LYSIPRESSIN) IN PLACENTAL MAMMALS - A REINVESTIGATION OF THE HIPPOPOTAMIDAE (HIPPOPOTAMUS-AMPHIBIUS) AND TAYASSUIDAE (TAYASSU-ANGULATUS) FAMILIES
10.1016/0016-6480(88)90277-8
EVOLUTION OF MARSUPIALS TRACED BY THEIR NEUROHYPOPHYSEAL HORMONES - MICROIDENTIFICATION OF MESOTOCIN AND ARGININE VASOPRESSIN IN 2 AUSTRALIAN FAMILIES, DASYURIDAE AND PHASCOLARCTIDAE
10.1016/0016-6480(87)90195-x
GUINEA-PIG NEUROHYPOPHYSEAL HORMONES - PECULIAR PROCESSING OF THE 3-DOMAIN VASOPRESSIN PRECURSOR
10.1016/0014-5793(87)81294-2
Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal
10.1210/me.2015-1211
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus
10.1128/jvi.00404-16
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Recent advances in human viruses imaging studies
10.1002/jobm.201500575
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/jvi.00192-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver
10.1186/1478-811x-12-4
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
HCV replication and assembly: a play in one act
10.2217/fvl.11.69
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/jvi.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/jvi.01190-09
LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice
10.1172/jci34997
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/jvi.00024-06
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/jvi.80.6.2832-2841.2006
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis
10.1038/sj.emboj.7600989
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/jvi.79.16.10826-10829.2005
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/s0074-7696(05)45006-8
Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon
10.1210/en.2004-1118
Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway
10.1074/jbc.M400508200
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/jvi.78.22.12591-12602.2004
Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells
10.1091/mbc.E02-06-0338
Dynamic processing of neuropeptides - Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport
10.1385/jmn:18:3:223
Yeast Vps55p, a functional homolog of human obesity receptor gene-related protein, is involved in late endosome to vacuole trafficking
10.1091/mbc.01-12-0597
Targeting of lysosomal proteins
10.1006/scdb.2000.0168
Unique evolution of neurohypophysial hormones in cartilaginous fishes: Possible implications for urea-based osmoregulation
10.1002/(sici)1097-010x(19991001)284:5<475::aid-jez2>3.0.co;2-9
Adaptive evolution of water homeostasis regulation in amphibians: Vasotocin and hydrins
10.1016/s0248-4900(97)83380-1
Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
10.1073/pnas.94.13.6646
Molecular evolution of neurohypophysial hormones in relation to osmoregulation: the two fish options
10.1023/a:1007720909113
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Endospanin1 affects oppositely body weight regulation and glucose homeostasis by differentially regulating central leptin signaling.
10.1016/j.molmet.2016.10.009
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
10.1128/jvi.00048-17
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics.
10.1016/j.jviromet.2017.04.009
Hepatitis C virus life cycle and lipid metabolism.
10.3390/biology3040892
Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity
10.1172/jci.insight.98081
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence
10.3390/v11020165
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses
10.1101/2021.05.19.444823
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal.
10.1074/jbc.ra119.008964
Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release.
10.1007/s00018-020-03745-y
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections
10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis
10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis
10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization
10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin
10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection
10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges
10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays
10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways
10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings
10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis
10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence
10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200076a
High-content screening in infectious diseases
10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ
10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery
10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure
10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems
10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans
10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis
10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva
10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images
10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues
10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents
10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence
10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics
10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions
10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex
10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides
10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro
10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase
10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides
10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions
10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays
10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation
10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening
10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections
10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation
10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells
10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria
10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.
10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.
10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Worms' Antimicrobial Peptides.
10.3390/md17090512
T(oo)bAd.
10.1038/s41589-019-0347-x
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Cell microbiology interview
10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
Francois HELLE
HELLE Francois
ORCID: 0000-0001-6884-2456
Biology of the BKPyV: An Update
10.3390/v9110327
Genetic recombination of the hepatitis C virus: clinical implications
10.1111/j.1365-2893.2010.01367.x
Simeprevir for the treatment of hepatitis C virus infection
10.2147/pgpm.s52715
The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
10.3390/v3101909
Hepatitis C virus entry into host cells
10.1007/s00018-007-7291-8
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Strong Correlation between Liver and Serum Levels of Hepatitis C Virus Core Antigen and RNA in Chronically Infected Patients
10.1128/jcm.06503-11
A new tool to study ribavirin-induced haemolysis
10.3851/imp2308
Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein
10.1128/jvi.02659-12
The antimalarial ferroquine is an inhibitor of hepatitis C virus
10.1002/hep.26273
Which therapeutic option for hepatitis C virus genotype 1?
10.3109/00365521.2014.978364
The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro
10.1016/j.antiviral.2015.03.012
Phylogenetic analysis of a circulating hepatitis C virus recombinant strain 1b/1a isolated in a French hospital centre
10.1016/j.meegid.2015.09.030
Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
10.1002/hep.29096
A Simple and Reliable Strategy for BK Virus Subtyping and Subgrouping
10.1128/jcm.01180-16
High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients
10.1007/s00705-017-3312-6
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
10.1371/journal.pone.0149064
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
10.1111/jvh.12767
Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review
10.1016/j.jcv.2018.10.002
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse
10.1097/ftd.0b013e3182966dee
Comparative Evaluation of Three Nucleic Acid-Based Assays for BK Virus Quantification
10.1128/jcm.02116-15
Alginate Hydrogel Protects Encapsulated Hepatic HuH-7 Cells against Hepatitis C Virus and Other Viral Infections
10.1371/journal.pone.0109969
DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase
10.1016/j.antiviral.2017.09.002
BK polyomavirus in the urine for follow-up of kidney transplant recipients
10.1016/j.cmi.2018.07.027
BK Polyomavirus Hijacks Extracellular Vesicles for En Bloc Transmission
10.1128/jvi.01834-19
No correlation between Torque Teno virus viral load and BK virus replication after kidney transplantation
10.1016/j.jcv.2019.03.018
The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies
10.1007/s00705-013-1862-9
Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes
10.1099/vir.0.049676-0
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions
10.1128/jvi.01548-10
The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein
10.1128/jvi.00127-07
Subcellular Localization of Hepatitis C Virus Structural Proteins in a Cell Culture System That Efficiently Replicates the Virus
10.1128/jvi.80.6.2832-2841.2006
In vitro infection of primary human hepatocytes by HCV-positive sera: insights on a highly relevant model
10.1136/gutjnl-2013-304623
Up-Regulation of the ATP-Binding Cassette Transporter A1 Inhibits Hepatitis C Virus Infection
10.1371/journal.pone.0092140
Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes
10.1136/gutjnl-2014-309011
β-Alkylated oligomaltosides as new alternative preservatives: antimicrobial activity, cytotoxicity and preliminary investigation of their mechanism of action
10.1111/jam.12301
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
10.1111/j.1365-2893.2008.01058.x
QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence
10.3390/v11020165
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein
10.1053/j.gastro.2017.09.020
Initiation of Hepatitis C Virus Infection Requires the Dynamic Microtubule Network
10.1074/jbc.m807873200
Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans
10.1074/jbc.m602431200
Comprehensive search for intra- and inter-specific sequence polymorphisms among coding envelope genes of retroviral origin found in the human genome: genes and pseudogenes
10.1186/1471-2164-6-117
N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins
10.1684/VIR.2009.0270
Entry of HCV into target cells
10.1684/VIR.2008.0163
Indoleamine 2,3-Dioxygenase Is Involved in Interferon Gamma’s Anti-BKPyV Activity in Renal Cells
10.3390/v12080865
Intercellular Transmission of Naked Viruses through Extracellular Vesicles: Focus on Polyomaviruses
10.3390/v12101086
Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
10.3389/fmicb.2020.584251
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
BK Polyomavirus Micro-RNAs: Time Course and Clinical Relevance in Kidney Transplant Recipients
10.3390/v13020351
Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis
10.3390/jcm10091815
Jannick Prentoe
Prentoe Jannick
ORCID: 0000-0003-2203-9478
Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7
10.1099/vir.0.053868-0
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies
10.1002/hep.26524
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein
10.1128/JVI.01941-12
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
10.1073/pnas.1114927109
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate
10.1371/journal.ppat.1002653
Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems
10.1371/journal.ppat.1002696
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step
10.1128/JVI.00586-11
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.
10.1128/JVI.01594-10
Hepatitis C virus expressing flag-tagged envelope protein 2 has unaltered infectivity and density, is specifically neutralized by flag antibodies and can be purified by affinity chromatography
10.1016/j.virol.2010.10.034
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs
10.1002/hep.22673
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization
10.1073/pnas.0711044105
Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a
10.1002/hep.27298
Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1–6
10.1016/j.virol.2014.03.021
Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.
10.1128/jvi.00039-15
Hypervariable Region 1 Shielding of Hepatitis C Virus Is a Main Contributor to Genotypic Differences in Neutralization Sensitivity
10.1002/hep.28705
Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A
10.1371/journal.ppat.1006214
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization
http://dx.doi.org/10.1128/JVI.01594-10
HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
10.1136/gutjnl-2015-310300
Hepatitis C Virus–Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance
10.1093/infdis/jiy481
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/JVI.01982-17
Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus
10.1128/JVI.02017-13
Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms
10.1128/JVI.01909-18
High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
10.1038/s41598-018-35010-5
Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies
10.1126/sciadv.aav1882
In vitro neutralization assay using cultured hepatitis C virus
10.1007/978-1-4939-8976-8_29
Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations
10.1073/pnas.1822002116
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design
10.1371/journal.ppat.1007772
Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency
10.3390/vaccines8020294
Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity
10.1126/sciadv.abb5938
An alternate conformation of HCV E2 neutralizing face as an additional vaccine target
10.1126/sciadv.abb5642
Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies
10.3390/vaccines9030291
Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins
10.1016/j.immuni.2021.02.013
Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens
10.1371/journal.pone.0255336
In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus
10.1371/journal.ppat.1009720
Jean Dubuisson
Dubuisson Jean
ORCID: 0000-0003-1626-7693
Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses
10.1016/j.jhep.2015.12.021
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
10.1371/journal.pone.0149064
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin
10.1016/j.antiviral.2016.07.011
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
10.1136/gutjnl-2015-311109
Alphacoronaviruses Detected in French Bats Are Phylogeographically Linked to Coronaviruses of European Bats
10.3390/v7122937
Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry
10.1039/c4nr03875d
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/JVI.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
HCV envelope glycoproteins in virion assembly and entry
10.2217/FVL.14.114
Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion
10.1128/JVI.00991-15
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/JVI.00192-15
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/JVI.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice
10.1002/bab.1223
Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution
10.1128/JVI.01745-13
HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin
10.3748/wjg.v20.i1.148
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Hepatitis C virus life cycle and lipid metabolism
10.3390/biology3040892
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
10.1371/journal.pone.0111333
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/JVI.01402-14
Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion
10.3390/v6031149
Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation
10.1016/j.vaccine.2014.01.046
Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents
10.1002/hep.27196
Virology and cell biology of the hepatitis C virus life cycle - An update
10.1016/j.jhep.2014.06.031
Additional Glycosylation Within a Specific Hypervariable Region of Subtype 3a of Hepatitis C Virus Protects Against Virus Neutralization
10.1093/infdis/jit376
Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein
10.1128/JVI.02659-12
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry
10.1111/cmi.12112
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics
10.1021/am403770q
Structural knowledge of HCV envelope protein region recognized by broadly neutralizing antibodies
10.2217/fvl.13.75
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Virus-neutralizing antibodies to hepatitis C virus
10.1111/jvh.12094
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
10.1136/gutjnl-2012-302048
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion
10.1074/jbc.M112.382341
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein
10.1099/vir.0.028092-0
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships
10.1099/vir.0.034314-0
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/AAC.00633-11
HCV replication and assembly: a play in one act
10.2217/FVL.11.69
Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype
10.1128/JVI.01332-10
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2
10.1128/JVI.02170-10
Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection
10.1074/jbc.M111.220103
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
10.3390/v3101909
Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus
10.1128/JVI.01180-10
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/JVI.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/JVI.01190-09
Last Stop Before Exit - Hepatitis C Assembly and Release as Antiviral Drug Targets
10.3390/v2081782
NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus
10.1074/jbc.M110.122895
Recent Advances in Hepatitis C Virus Cell Entry
10.3390/v2030692
Role of lipid metabolism in hepatitis C virus assembly and entry
10.1042/BC20090125
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions
10.1128/JVI.01548-10
Enhanced anti-HCV activity of interferon alpha 17 subtype
10.1186/1743-422X-6-70
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
10.1111/j.1365-2893.2008.01058.x
N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins
10.1684/vir.2009.0270
Occludin, the final essential factor for HCV entry?
10.2217/FVL.09.13
Rapid synchronization of hepatitis C virus infection by magnetic adsorption
10.1016/j.jviromet.2008.11.015
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
10.1186/1471-2180-9-111
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein
10.1128/JVI.02582-07
Hepatitis C virus entry into host cells
10.1007/s00018-007-7291-8
Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus
10.1086/589777
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent
10.1128/JVI.01443-07
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection
10.1128/JVI.01573-06
Hepatitis C virus proteins
10.3748/wjg.v13.i17.2406
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus
10.1073/pnas.0705522104
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
10.1186/1742-4690-4-8
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors
10.1099/vir.0.82465-0
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes
10.1007/s00232-007-9003-6
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein
10.1128/JVI.00127-07
Transmembrane domains of hepatitis C virus envelope glycoproteins: Residues involved in E1E2 heterodimerization and involvement of these domains in virus entry
10.1128/JVI.02198-06
Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles
10.1099/vir.0.81503-0
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans
10.1074/jbc.M602431200
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/JVI.00024-06
Hepatitis C virus entry: potential receptors and their biological functions
10.1099/vir.0.81646-0
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI
10.1074/jbc.M602706200
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry
10.1099/vir.0.81932-0
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system
10.1002/hep.21406
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/JVI.80.6.2832-2841.2006
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2
10.1128/JVI.79.21.13199-13208.2005
Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets
10.1099/vir.0.81169-0
Basic residues in hyervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry
10.1128/JVI.79.24.15331-15341.2005
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/JVI.79.16.10826-10829.2005
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus
10.1002/hep.20542
Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer
10.1099/vir.0.81140-0
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I
10.1074/jbc.M411600200
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/S0074-7696(05)45006-8
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins
10.1128/JVI.79.13.8400-8409.2005
Characterization of functional hepatitis C virus envelope glycoproteins
10.1128/JVI.78.6.2994-3002.2004
Functional hepatitis C virus envelope glycoproteins
10.1016/j.biolcel.2004.03.008
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions
10.1128/JVI.78.17.9224-9232.2004
Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein
10.4049/jimmunol.173.1.446
Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication
10.1007/s00705-003-0291-6
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions
10.1074/jbc.M406315200
Structural biology of hepatitis C virus
10.1002/hep.20032
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/JVI.78.22.12591-12602.2004
Another putative receptor for hepatitis C virus
10.1002/hep.510370327
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
10.1128/JVI.77.19.10677-10683.2003
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
10.1074/jbc.M305289200
Characterization of the expression of the hepatitis C virus F protein
10.1099/vir.0.19065-0
Glycosylation of hepatitis C virus envelope proteins
10.1016/S0300-9084(03)00004-X
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
10.1084/jem.20021756
Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope
10.1128/JVI.77.2.813-820.2003
Topology of hepatitis C virus envelope glycoproteins
10.1002/rmv.391
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines
10.1128/JVI.76.3.1181-1193.2002
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line
10.1093/glycob/12.2.95
Interaction of hepatitis C virus proteins with host cell membranes and lipids
10.1016/S0962-8924(02)02383-8
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines
10.1006/viro.2001.1212
Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment
10.1074/jbc.M111020200
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
10.1128/JVI.76.8.3720-3730.2002
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins
10.1093/emboj/cdf295
Biogenesis of hepatitis C virus envelope glycoproteins
10.1099/0022-1317-82-11-2589
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2
10.1099/0022-1317-82-7-1629
Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization
10.1053/jhep.2001.22175
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients
10.1128/JVI.75.17.8240-8250.2001
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10.1128/JVI.74.8.3623-3633.2000
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding
10.1099/0022-1317-81-12-2873
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
10.1128/JVI.74.2.702-709.2000
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein
10.1074/jbc.M004326200
Reciprocal relationship between alpha 1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells
10.1046/j.1432-1327.2000.01111.x
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization
10.1074/jbc.M003003200
Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex
10.1099/0022-1317-80-4-887
Characterization of aggregates of hepatitis C virus glycoproteins
10.1099/0022-1317-80-12-3099
Retention and degradation of N-glycoproteins in the rough endoplasmic reticulum
10.1023/A:1020228725997
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties
10.1006/viro.1998.9202
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
10.1074/jbc.273.48.32088
Characterization of truncated forms of hepatitis C virus glycoproteins
10.1099/0022-1317-78-9-2299
SYNTHESIS AND PROCESSING OF BOVINE HERPESVIRUS-1 GLYCOPROTEIN-H
10.1016/S0042-6822(95)80083-2
ATTACHMENT OF THE GAMMAHERPESVIRUS BOVINE HERPESVIRUS-4 IS MEDIATED BY THE INTERACTION OF GP8 GLYCOPROTEIN WITH HEPARIN-LIKE MOIETIES ON THE CELL-SURFACE
10.1006/viro.1993.1471
IDENTIFICATION OF 108-K, 93-K, AND 42-K GLYCOPROTEINS OF BOVINE HERPESVIRUS-1 BY MONOCLONAL-ANTIBODIES
10.1007/BF01309747
EPIDEMIOLOGIC EVALUATION OF A MONOCLONAL ELISA DETECTING BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGENS IN FIELD BLOOD-SAMPLES OF PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(92)90010-B
IDENTIFICATION AND CHARACTERIZATION OF GLYCOPROTEIN-GP1 OF BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-73-5-1293
MECHANISMS OF BOVINE HERPESVIRUS TYPE-1 NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO GLYCOPROTEIN-GI, GLYCOPROTEIN-GIII AND GLYCOPROTEIN-GIV
10.1099/0022-1317-73-8-2031
MOLECULAR-BIOLOGY OF BOVINE HERPESVIRUS TYPE-4
10.1016/0378-1135(92)90037-T
PROTEINS OF BOVINE HERPESVIRUS TYPE-4 RELEASED INTO THE CULTURE-MEDIUM OF PRODUCTIVELY INFECTED-CELLS - IDENTIFICATION OF A 135K GLYCOPROTEIN INVOLVED IN VIRAL ATTACHMENT
10.1099/0022-1317-73-1-189
A MONOCLONAL ELISA FOR BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGEN-DETECTION IN PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(91)90133-K
ANTIGENIC AND GENOMIC IDENTITY BETWEEN SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-3-715
BOVINE HERPESVIRUS-4 ISOLATES - A COMPARISON OF 3 MAJOR GLYCOPROTEINS
10.1016/0378-1135(91)90132-Y
CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVINE VIRAL DIARRHEA VIRUS - EVIDENCE OF A NEUTRALIZING ACTIVITY AGAINST GP48 IN THE PRESENCE OF GOAT ANTI-MOUSE IMMUNOGLOBULIN SERUM
10.1099/0022-1317-72-5-1195
COMPARISON OF PROTEINS OF SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-5-1145
FAILURE TO INFECT CATS WITH BOVINE HERPESVIRUS TYPE-4 STRAIN MOVAR 33/63
10.1136/vr.128.26.614
GENOMIC DIVERSITY AMONG BOVINE HERPESVIRUS-4 FIELD ISOLATES
10.1007/BF01319227
TEMPORAL CONTROL OF BOVINE HERPESVIRUS TYPE-4 GLYCOPROTEIN-SYNTHESIS
10.1099/0022-1317-72-6-1429
Bovine herpesvirus 4 genome: cloning, mapping and strain variation analysis
10.1099/0022-1317-71-1-133
Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization
10.1099/0022-1317-71-3-647
EXPERIMENTAL-INFECTION OF BULLS WITH A GENITAL ISOLATE OF BOVINE HERPESVIRUS-4 AND REACTIVATION OF LATENT VIRUS WITH DEXAMETHASONE
10.1016/0378-1135(89)90022-9
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVID HERPESVIRUS-4
10.1016/0378-1135(89)90096-5
PROTEINS SPECIFIED BY BOVINE HERPESVIRUS TYPE-4 - STRUCTURAL PROTEINS OF THE VIRION AND IDENTIFICATION OF 2 MAJOR GLYCOPROTEINS BY USING MONOCLONAL-ANTIBODIES
10.1099/0022-1317-70-7-1743
BIOLOGICAL AND BIOCHEMICAL-COMPARISON OF BOVID HERPESVIRUS-4 STRAINS
10.1016/0378-1135(88)90015-6
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly
10.1128/JVI.00048-17
Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination
10.1111/pbi.12743
Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly
10.1016/j.biochi.2017.06.009
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics
10.1016/j.jviromet.2017.04.009
Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes
10.1128/JVI.00478-17
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
10.1111/jvh.12767
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1
10.1016/j.virol.2017.10.019
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein
10.1053/j.gastro.2017.09.020
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes
10.1053/j.gastro.2018.03.020
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)
10.1007/s40271-017-0232-1
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
10.1371/journal.pone.0145105
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
10.1111/jvh.12433
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain
10.1128/JVI.00939-18
HCoV-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2 ' region
10.1099/jgv.0.001074
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies
10.3389/fimmu.2018.00910
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication
10.1101/469361
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/JVI.02009-18
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir
10.1016/j.antiviral.2019.05.002
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1038/s41598-019-42737-2
Le virus de l’hépatite E
10.1051/medsci/2018299
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture
10.1371/journal.pone.0198226
Function of the HCV E1 envelope glycoprotein in viral entry and assembly
10.2217/fvl-2018-0180
Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV
10.1007/978-1-4939-8976-8_2
Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit
10.1016/j.jcv.2019.104206
A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice
10.1186/s12879-019-4571-5
Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver
10.3390/cells8101296
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
10.1021/acsami.9b15032
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
10.1074/jbc.ra119.008964
Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection
10.1111/tra.12680
Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model
10.1101/2020.04.22.056754
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
Les coronavirus, ennemis incertains
10.1051/medsci/2020113
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource
10.1016/j.jep.2020.112735
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
10.3390/microorganisms9020339
Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds
10.3390/pathogens10070861
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
Jens Bukh
Bukh Jens
ORCID: 0000-0002-7815-4806
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro
10.1128/AAC.02680-20
Broadening CD4(+) and CD8(+) T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes
10.1128/JVI.00130-17
Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems
10.1371/journal.ppat.1002696
Development of a TaqMan assay for the six major genotypes of hepatitis C virus: Comparison with commercial assays
10.1002/jmv.21043
In vivo study of the HC-TN strain of hepatitis C Virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells
10.1128/JVI.01774-06
Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses
10.1371/journal.pone.0062674
Failure to infect rhesus monkeys with hepatitis C virus strains of genotypes 1a, 2a or 3a
10.1046/j.1365-2893.2001.00284.x
HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
10.1136/gutjnl-2015-310300
Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in denmark
10.1371/journal.pone.0113034
Monitoring of hepatitis C virus quasispecies in chronic infection by matrix-assisted laser desorption ionization-time of flight mass spectrometry mutation detection
10.1128/JCM.02512-06
Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain
10.4049/jimmunol.1001877
Five new or recently discovered (GBV-A) virus species are indigenous to new world monkeys and may constitute a separate genus of the Flaviviridae
10.1006/viro.1997.8461
High Prevalence of Hepatitis C Virus (HCV) RNA in Dialysis Patients: Failure of Commercially Available Antibody Tests to Identify a Significant Number of Patients with HCV Infection
10.1093/infdis/168.6.1343
Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity
10.1002/hep.28705
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies
10.1002/hep.26524
A critical role for the chimpanzee model in the study of hepatitis C
10.1002/hep.20268
Quasispecies in viral persistence and pathogenesis of hepatitis C virus
10.1016/S0966-842X(99)01590-5
Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family
10.1099/jgv.0.000612
Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
10.1371/journal.ppat.1004128
Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death
10.1016/j.virol.2008.03.027
High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis: Frequent mixed infections with different genotypes and lack of evidence of associated liver disease
10.1002/(SICI)1096-9071(199911)59:3<313::AID-JMV9>3.0.CO;2-B
Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a
10.1002/hep.27298
Genetic epidemiology of hepatitis C virus throughout Egypt
10.1086/315786
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains
10.1073/pnas.1203829109
The challenge of developing a vaccine against hepatitis C virus
10.1016/S0168-8278(02)00308-2
Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A
10.1128/JVI.00049-11
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain
10.1128/JVI.00142-08
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1
10.1073/pnas.0501275102
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
10.1002/hep.20819
Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins
10.1099/vir.0.015750-0
High-level expression of hepatitis C virus (HCV) structural proteins by a chimeric HCV/BVDV genome propagated as a BVDV pseudotype
10.1016/S0166-0934(01)00339-1
Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study
10.1186/1471-2334-11-177
How Escherichia coli can bias the results of molecular cloning: Preferential selection of defective genomes of hepatitis C virus during the cloning procedure
10.1073/pnas.94.25.13909
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): Genetic analyses and in vivo pathogenesis studies
10.1128/JVI.02667-09
Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir
10.1053/j.gastro.2016.07.013
Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7
10.1099/vir.0.053868-0
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs
10.1002/hep.22673
Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort
10.1111/j.1365-2893.2010.01392.x
Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry
10.1128/JVI.00684-12
Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: Failure of homologous neutralizing-antibody treatment to control infection
10.1086/593021
Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle
10.1128/AAC.02929-15
Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients
10.1128/JCM.41.3.1091-1100.2003
Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface
10.1006/viro.2000.0419
Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization
10.1007/s007050050479
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization
10.1073/pnas.0711044105
Transcripts of a chimeric CDNA clone of hepatitis C virus genotype 1b are infectious in vivo
10.1006/viro.1998.9092
Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection
10.1002/jmv.24537
Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor
10.1128/AAC.01176-13
Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively
10.1093/infdis/jir631
Sequence analysis of the core gene of 14 hepatitis C virus genotypes
10.1073/pnas.91.17.8239
Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus
10.1093/infdis/jir511
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus
10.1002/hep.24171
DNA-based vaccination against hepatitis C virus (HCV): Effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice
10.1016/S0264-410X(02)00304-3
Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees
10.1073/pnas.212532699
Differential sensitivity of 5′UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors
10.1053/j.gastro.2013.11.009
The GB viruses: A review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae
10.1099/vir.0.027490-0
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease
10.1073/pnas.202608299
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes
10.1002/hep.26744
Animal models of hepatitis C virus infection
10.1002/9781118637272.ch19
Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae
10.1099/jgv.0.000873
Combination treatment with hepatitis c virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses
10.1128/AAC.02164-12
Diagnostic and clinical implications of the different genotypes of hepatitis C virus
10.1002/hep.1840200139
Immunity against the GBV-B hepatitis virus in tamarins can prevent productive infection following rechallenge and is long-lived
10.1002/jmv.21013
Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations
10.1128/JVI.01605-10
Molecular and epidemiological profiles of hepatitis C virus genotype 4 in Denmark
10.1002/jmv.21896
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
10.1073/pnas.1114927109
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
10.1371/journal.pone.0059776
Recombinant HCV variants with NS5A from genotypes 17 have different sensitivities to an NS5A inhibitor but not interferon-α
10.1053/j.gastro.2010.11.036
Correlates of spontaneous clearance of hepatitis C virus in a Danish human immunodeficiency virus type 1 cohort
10.3109/00365548.2011.589077
Comparative analysis of the molecular mechanisms of recombination in hepatitis C virus
10.1016/j.tim.2014.02.005
Studies of hepatitis C virus in chimpanzees and their importance for vaccine development
10.1159/000050040
Efficient hepatitis c virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors
10.1128/AAC.00037-17
Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance
10.1128/AAC.01953-15
Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A
10.1371/journal.ppat.1006214
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate
10.1371/journal.ppat.1002653
Productive Homologous and Non-homologous Recombination of Hepatitis C Virus in Cell Culture
10.1371/journal.ppat.1003228
Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus
10.1128/JVI.02017-13
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: Replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models
10.1086/651579
Importance of the polymerase chain reaction in the study of hepatitis C virus infection
10.1007/BF02592298
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
10.1053/j.gastro.2011.06.004
Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature
10.1016/j.virol.2011.10.023
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein
10.1128/JVI.01941-12
Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77
10.1128/JVI.02877-14
Functional analyses of GB virus B p13 protein: Development of a recombinant GB virus B hepatitis virus with a p7 protein
10.1073/pnas.0511297103
Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: A Danish cohort study
10.1111/j.1365-2893.2009.01126.x
Adaptive mutations enhance assembly and cell-to-cell transmission of a high-titer hepatitis C virus genotype 5a Core-NS2 JFH1-based recombinant
10.1128/JVI.00039-15
Immunoglobulin with high-titer in vitro cross-neutralizing hepatitis C virus antibodies passively protects chimpanzees from homologous, but not heterologous, challenge
10.1128/JVI.01194-15
Genomic analysis of the host response to hepatitis C virus infection
10.1073/pnas.202608199
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain
10.1002/hep.22244
Sequence analysis of the 5' noncoding region of hepatitis C virus
10.1073/pnas.89.11.4942
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system
10.1073/pnas.1218260109
Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein
10.1016/j.virusres.2005.06.009
Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8¿ T cells in early viral evolution
10.1128/JVI.02654-10
Transfusion-associated hepatitis before the screening of blood for hepatitis risk factors
10.1111/trf.12682
In vivo analysis of the 3′ untranslated region of GB virus B after in vitro mutagenesis of an infectious cDNA clone: Persistent infection in a transfected tamarin
10.1128/JVI.78.17.9389-9399.2004
Persistent human hepatitis B virus infection in cynomolgus monkeys
10.1002/hep.26560
Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a/2a (S52/JFH1) Viruses
10.1053/j.gastro.2007.08.005
Hepatitis C virus expressing flag-tagged envelope protein 2 has unaltered infectivity and density, is specifically neutralized by flag antibodies and can be purified by affinity chromatography
10.1016/j.virol.2010.10.034
Current status of a hepatitis C vaccine: Encouraging results but significant challenges ahead
10.1007/s11908-007-0003-6
Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.
10.1016/S0065-3527(08)00002-X
Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles
10.1111/j.1365-2893.2009.01111.x
Hepatitis C virus : An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic la and 2a chimeras
10.1006/viro.1999.9889
A milestone for hepatitis C virus research: A virus generated in cell culture is fully viable in vivo
10.1073/pnas.0600551103
Genetic variants in the apoptosis gene bcl2l1 improve response to interferon-based treatment of hepatitis c virus genotype 3 infection
10.3390/ijms16023213
Natural History and Experimental Models
10.1002/9780470987131.ch27
Mouse models of acute and chronic hepacivirus infection
10.1126/science.aal1962
Hepatitis C virus-host cell interactions uncovered
10.1073/pnas.0705890104
Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee
10.1073/pnas.94.16.8738
Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against specific antagomir
10.1099/jgv.0.000445
Hepatitis C virus lacking the hypervariable region 1 of thesecond envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees
10.1073/pnas.230453597
Hepatitis C virus envelope protein E2 binds to CD81 of tamarins
10.1006/viro.2000.0617
In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes
10.1073/pnas.2335981100
Non-genotype-specific role of the hepatitis C virus 5′ untranslated region in virus production and in inhibition by interferon
10.1016/j.virol.2011.10.002
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences
10.1073/pnas.1834545100
Hepatitis C homolog in dogs with respiratory illness
10.1073/pnas.1107612108
Amplification of the full-length hepatitis A virus genome by long reverse transcription-PCR and transcription of infectious RNA directly from the amplicon
10.1073/pnas.93.9.4370
Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells
10.1128/AAC.01256-12
Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C
10.3109/00365521.2012.694905
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus
10.1073/pnas.0800422105
Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6
10.1016/j.virol.2014.03.021
A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species
10.1073/pnas.211424698
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes
10.1002/hep.21377
Animal models for the study of hepatitis C virus infection and related liver disease
10.1053/j.gastro.2012.02.016
The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control
10.1016/j.jhep.2016.07.035
Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in new world monkeys and chimpanzees
10.1002/jmv.2092
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization
10.1128/JVI.01594-10
Neutralizing monoclonal antibodies against hepatitis C Virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step
10.1128/JVI.00586-11
Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors
10.1002/hep.26660
ICTV virus taxonomy profile: Flaviviridae
10.1099/jgv.0.000672
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus
10.1128/JVI.01872-07
Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance
10.1128/JVI.00901-13
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR
10.1073/pnas.1016606108
Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent
10.1006/viro.1999.9941
DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface
10.1016/S0264-410X(98)00448-4
Genetic variation in toll-like receptors and retinoic acid-inducible gene I and outcome of hepatitis C virus infection
10.1111/jvh.12188
The quasispecies of hepatitis C virus and the host immune response
10.1007/BF00945022
Functional analyses of GB virus B p13 protein: Development of a recombinant GB virus B hepatitis virus with a p7 protein
http://dx.doi.org/10.1073/pnas.0511297103
Viral hepatitis
10.1038/nrgastro.2013.136
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization
http://dx.doi.org/10.1128/JVI.01594-10
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape Variants
10.1053/j.gastro.2017.12.015
Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses
http://dx.doi.org/10.1053/j.gastro.2007.08.005
A milestone for hepatitis C virus research: a virus generated in cell culture is fully viable in vivo.
http://dx.doi.org/10.1073/pnas.0600551103
Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a
10.1099/jgv.0.001095
Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies
10.1016/j.virol.2018.05.020
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/JVI.01982-17
A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus
10.1016/j.jcv.2018.05.012
High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
10.1038/s41598-018-35010-5
Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies
10.1126/sciadv.aav1882
In vitro neutralization assay using cultured hepatitis C virus
10.1007/978-1-4939-8976-8_29
Full-length open reading frame amplification of hepatitis C virus
10.1007/978-1-4939-8976-8_5
Hepatitis C Virus–Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance
10.1093/infdis/jiy481
Hepatitis C virus escape studies for human antibody AR3A reveals a high barrier to resistance and novel insights on viral antibody evasion mechanisms.
10.1128/jvi.01909-18
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
10.1016/j.jhep.2018.10.031
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
10.1097/meg.0000000000001192
Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
10.3389/fimmu.2018.02146
Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
10.1016/j.antiviral.2018.07.014
Direct acting antiviral treatment of chronic hepatitis C in Denmark
10.1080/00365521.2018.1467963
Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model
10.1038/s41598-018-22620-2
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.
10.1016/j.virusres.2018.02.016
HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models
10.1053/j.gastro.2018.02.017
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis c virus infections uncover molecular determinants for E2 targeting and vaccine design
10.1371/journal.ppat.1007772
Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations
10.1073/pnas.1822002116
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
10.1002/hep.30647
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
10.1128/JVI.00733-19
HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen
10.1038/s41598-019-50365-z
Genome sequence of an unknown subtype of hepatitis C virus genotype 6
10.1128/MRA.01030-19
Virus adaptation and selection following challenge of animals vaccinated against classical swine fever virus
10.3390/v11100932
Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent
10.1016/j.virol.2019.09.014
Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell–Based Vaccine Development
10.1053/j.gastro.2019.11.282
Cell culture studies of the efficacy and barrier to resistance of sofosbuvir-velpatasvir and glecaprevir-pibrentasvir against hepatitis C virus genotypes 2a, 2b, and 2C
10.1128/AAC.01888-19
Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro
10.3390/proceedings2020050005
Evolutionary selection of pestivirus variants with altered or no microRNA dependency
10.1093/nar/gkaa300
Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency
10.3390/vaccines8020294
Equine pegiviruses cause persistent infection of bone marrow and are not associated with hepatitis
10.1371/journal.ppat.1008677
Analysis of virus population profiles within pigs infected with virulent Classical Swine Fever viruses; evidence for bottlenecks in transmission but absence of tissue specific virus variants
10.1128/JVI.01119-20
Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity
10.1126/sciadv.abb5938
Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine
10.1038/s41598-020-72328-5
An alternate conformation of HCV E2 neutralizing face as an additional vaccine target
10.1126/sciadv.abb5642
Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity
10.1128/AAC.01417-20
Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon
10.1099/jgv.0.001486
Identification of specific amino acid residues in the border disease virus glycoprotein E2 that modify virus growth in pig cells but not in sheep cells
10.1099/jgv.0.001483
Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome
10.1111/jvh.13430
Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1–3 Strains and Does Not Correlate with Virus Replication
10.3390/v13030389
Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins
10.1016/j.immuni.2021.02.013
Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication
10.1128/AAC.00097-21
SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor
10.3390/vaccines9070706
In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms
10.3389/fmicb.2021.698944
In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus
10.1371/journal.ppat.1009720
In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
10.1038/s41598-021-93361-y
Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens
10.1371/journal.pone.0255336
Vaccines against hepatitis C
10.1136/gutjnl-2020-323377
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
10.1016/j.ebiom.2021.103519
